NY S07699

Expands medication-assisted treatment coverage to include all buprenorphine products, methadone, and long-acting injectable naltrexone for substance use disorder treatment when prescribed according to national professional guidelines.

Eliminates prior authorization requirements for buprenorphine products, methadone, and long-acting injectable naltrexone across Medicaid and managed care providers, replacing prior restrictions that had carve-outs for non-preferred or non-formulary forms.

Broadens coverage from opioid addiction treatment specifically to all substance use disorders.

Takes effect 90 days after enactment, with the managed care provider provision subject to repeal as previously scheduled.